Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06321497

Extracorporeal Carbon Dioxide Removal Using PrismaLung in Reducing Ventilator Induced Lung Injury

Measuring the Impact of Extracorporeal Carbon Dioxide Removal Using PrismaLung in Reducing Ventilator Induced Lung Injury in Mechanically Ventilated Patients

Status
Recruiting
Phase
Study type
Observational
Enrollment
15 (estimated)
Sponsor
Peninsula Health · Other Government
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Lung protective ventilation with low tidal volumes and low driving pressure are known to reduce mortality in mechanically ventilated patients with acute respiratory failure. This reduction in mortality is known be due to reduction of ventilator induced lung injury that occurs due to high tidal volumes and high driving pressure. When receiving such mechanical ventilation, some patients develop hypercapnia and associated hypercapnic acidosis. Such patients have an increased risk of mortality. While the exact reasons for such increase in mortality is not known, it is recommended to minimise hypercapnia and hypercapnic acidosis during lung protective ventilation. Minimally invasive extracorporeal carbon dioxide removal (ECCO2R) devices are shown to reduce hypercapnia and hypercapnic acidosis. There are several devices that are currently available in the current clinical practice. However, the effect of these devices on reduction in ventilator induced lung injury is not clearly demonstrated. This study aims to assess the use of an ECCO2R device called Prismalung in reducing ventilator induced lung injury. PrismaLung is currently used in our intensive care unit. This assessment is done by measuring interleukins in bronchoalveolar lavage fluid and blood interleukin levels as well as clinical assessment including the reduction of driving pressure.

Conditions

Interventions

TypeNameDescription
DEVICEExtracorporeal carbon dioxide removalLow flow extracorporeal carbon dioxide removal with PrismaLung+

Timeline

Start date
2024-02-05
Primary completion
2027-02-28
Completion
2028-02-28
First posted
2024-03-20
Last updated
2024-03-20

Locations

1 site across 1 country: Australia

Source: ClinicalTrials.gov record NCT06321497. Inclusion in this directory is not an endorsement.